Drugs / Valsartin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00130156 Background | Oct 2005 → Sep 2008 | benign essential hypertension | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Valsartin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00130156 ↗ |
| Known as | Diovan | “After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks.” NCT00130156 ↗ |